Evaluating the controlled reopening of nightlife during the COVID-19 pandemic: a matched cohort study in Sitges, Spain, in May 2021 (Reobrim Sitges).


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
01 06 2022
Historique:
entrez: 1 6 2022
pubmed: 2 6 2022
medline: 7 6 2022
Statut: epublish

Résumé

To assess the impact of relaxing the state of alarm restrictions on SARS-CoV-2 infections at 14 days among people attending reopened nightclub venues. Matched cohort study with a paired control group (1:5 ratio). Five small nightclubs with indoor areas and outdoor terraces, in a nightlife-restricted area in Sitges, Spain, on 20 May 2021. Wearing masks was mandatory, drinking was allowed and social distance was not required. Volunteers were selected through a convenience sampling. To attend the event, participants were required to be older than 17 years, with a negative rapid antigen diagnostic test (Ag-RDT) on the same afternoon, without a positive reverse-transcription PCR (RT-PCR) or Ag-RDT and/or symptoms associated with COVID-19 in the previous 7 days, to not having knowingly been in close contact with someone infected in the previous 10 days and to not have knowingly had close contact with someone with a suspicion of COVID-19 in the previous 48 hours. A control group was paired by exact age, gender, residence municipality, socioeconomic index, previous SARS-CoV-2-confirmed infection and vaccination status, in a 1:5 ratio, from the primary care electronic health records. Evidence of infection at electronic health records by SARS-CoV-2 at 14-day follow-up. Among the 391 participants (median age 37 years; 44% (n=173) women), no positive SARS-CoV-2 cases were detected at 14 days, resulting in a cumulative incidence estimation of 0 (95% CI 0 to 943) per 100 000 inhabitants. In the control group, two cases with RT-PCR test were identified, resulting in a cumulative incidence of 102.30 (12.4 to 369) per 100 000 inhabitants. Nightlife attendance under controlled conditions and with a requirement for a negative Ag-RDT was not associated with increased transmissibility of SARS-CoV-2 in a pandemic context of low infection rates. In such circumstances, secure opening of the nightlife sector was possible, under reduced capacity and controlled access by Ag-RDT, and environments where compliance with sanitary measures are maintainable.

Identifiants

pubmed: 35649590
pii: bmjopen-2021-058595
doi: 10.1136/bmjopen-2021-058595
pmc: PMC9160590
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e058595

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Gac Sanit. 2008 May-Jun;22(3):179-87
pubmed: 18579042
Lancet. 2021 Apr 17;397(10283):1425-1427
pubmed: 33609444
J Travel Med. 2020 May 18;27(3):
pubmed: 32307549
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Environ Res. 2020 Sep;188:109819
pubmed: 32569870
Ann Intern Med. 2021 Oct;174(10):1487-1488
pubmed: 34280335
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Lancet Infect Dis. 2021 Oct;21(10):1365-1372
pubmed: 34051886
Expert Rev Anti Infect Ther. 2021 Oct;19(10):1325-1330
pubmed: 33759682
Viruses. 2020 May 26;12(6):
pubmed: 32466458
Lancet Respir Med. 2020 Jul;8(7):658-659
pubmed: 32473123
J Stud Alcohol Drugs. 2021 Jan;82(1):42-54
pubmed: 33573721
Lancet. 2020 Apr 4;395(10230):1096-1099
pubmed: 32203693
J Travel Med. 2020 Aug 20;27(5):
pubmed: 32584403
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
Cureus. 2020 Dec 29;12(12):e12365
pubmed: 33527047
Lancet Infect Dis. 2021 Sep;21(9):e290-e295
pubmed: 33636148

Auteurs

Oriol Cunillera Puértolas (O)

Unitat de Suport a la Recerca Costa de Ponent, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Cornellà de Llobregat, Spain.
Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Spain.

Sara Contreras-Martos (S)

Unitat de Suport a la Recerca Costa de Ponent, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Cornellà de Llobregat, Spain.
Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Spain.

Mercè Marzo-Castillejo (M)

Unitat de Suport a la Recerca Costa de Ponent, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Cornellà de Llobregat, Spain.
Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Spain.

Darío López Gallegos (D)

Servei d'Atenció Primària Alt Penedès-Garraf-Baix Llobregat Nord, Direcció d'Atenció Primària Costa de Ponent, Institut Catala De La Salut, L'Hospitalet de Llobregat, Spain.

Mateo Acedo Anta (M)

Secretaria Tècnica, Direcció d'Atenció Primària Costa de Ponent, Institut Català de la Salut, Cornellà de Llobregat, Spain.
Escola d'Infermeria, Facultat de Medicina i Ciencies de la Salut, Universitat de Barcelona, Barcelona, Spain.

Jesús Almeda Ortega (J)

Unitat de Suport a la Recerca Costa de Ponent, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Cornellà de Llobregat, Spain.
Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Spain.

Joan Colom (J)

Subdirecció General de Drogodependències, Agència de Salut Pública de Catalunya. Departament de Salut, Generalitat de Catalunya, Barcelona, Spain.

Josep Basora (J)

Direcció, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.

Betlem Salvador-Gonzalez (B)

Unitat de Suport a la Recerca Costa de Ponent, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Cornellà de Llobregat, Spain bsalvador@ambitcp.catsalut.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH